Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagn... by Simon Bond, David Dunger, Mark Wilson, Adrian Mander, Mikael Knip, Anita Chhabra, M Loredana Marcovecchio, Charlotte S Wilhelm-Benartzi, Michael J Haller, Timothy Tree, Hilde Morobé, Sarah E Miller, Sylvaine Bruggraber, Diane Picton, Katrina Gatley, A Emile J Hendriks, Bärbel Aschemeier-Fuchs, Lut Overbergh, Jaivier Pall, Olivier Arnaud, Almut Nitsche, Anke M Schulte

Get full text